Oncolytic measles virus encoding thyroidal sodium iodide symporter(Vyriad, Inc.)(Oncolytic measles virus encoding thyroidal sodium iodide symporter(Vyriad, Inc.))

概要

基本信息

药物类型

溶瘤病毒

别名

MV NIS、MVNIS、Sodium Iodide Simporter Measles Virus

+ [2]

靶点

NIS

作用方式

调节剂

作用机制

NIS调节剂(solute carrier family 5 member 5 modulators)、免疫调节剂

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病+ [3]

在研适应症

输卵管癌卵巢癌腹膜癌+ [6]

非在研适应症

胶质母细胞瘤头颈部肿瘤血液肿瘤+ [3]

原研机构

Vyriad, Inc.初创企业

在研机构

Vyriad, Inc.初创企业

非在研机构

University of Arkansas System

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

7

项与 Oncolytic measles virus encoding thyroidal sodium iodide symporter(Vyriad, Inc.) 相关的临床试验

NCT03171493

/ Completed临床1期

Neoadjuvant Intravesical NIS Measles Virus (MV-NIS) in Patients Undergoing Cystectomy for Urothelial Carcinoma But Ineligible for Neoadjuvant Cisplatin-based Chemotherapy

This is a Phase 1 study designed to test the tolerability and feasibility of intravesical therapy with an attenuated Measles virus (MV-NIS) in patients with urothelial carcinoma who are undergoing radical cystectomy but are ineligible or do not desire neoadjuvant chemotherapy.

开始日期2018-07-20

申办/合作机构

Vyriad, Inc.初创企业

[+1]

NCT02919449

/ Terminated临床1期

Phase 1 Dose Escalation Trial of Intra-Tumoral Injection of Sodium Iodide Simporter (NIS) Measles Virus (Edmonston Strain) in Combination With Atezolizumab in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)

This a Phase 1 study designed to determine the maximum tolerated dose (MTD) and toxicity of attenuated Measles virus (MV-NIS) combined with Atezolizumab in patients with recurrent and metastatic NSCLC.

开始日期2017-08-03

申办/合作机构

Vyriad, Inc.初创企业

NCT02700230

/ Completed临床1期IIT

Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured from a Genetically Engineered Strain of Measles Virus in Patients with Unresectable or Recurrent Malignant Peripheral Nerve Sheath Tumor

This phase I trial studies the side effects and the best dose of a vaccine therapy in treating patients with malignant peripheral nerve sheath tumor that cannot be removed by surgery (unresectable) or has come back after a period of improvement (recurrent). Vaccines made from a gene-modified virus may kill tumor cells expressing a gene called neurofibromin 1 (NF1) without affecting surrounding normal cells and may also help the body build an effective immune response to kill tumor cells.

开始日期2017-03-22

申办/合作机构

Mayo Clinic

100 项与 Oncolytic measles virus encoding thyroidal sodium iodide symporter(Vyriad, Inc.) 相关的临床结果

登录后查看更多信息

100 项与 Oncolytic measles virus encoding thyroidal sodium iodide symporter(Vyriad, Inc.) 相关的转化医学

登录后查看更多信息

100 项与 Oncolytic measles virus encoding thyroidal sodium iodide symporter(Vyriad, Inc.) 相关的专利（医药）

登录后查看更多信息

17

项与 Oncolytic measles virus encoding thyroidal sodium iodide symporter(Vyriad, Inc.) 相关的文献（医药）

2024-07-01·eBioMedicine

Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures

Article

作者: Schröer, Katrin ; Marchini, Antonio ; Hawinkels, Lukas J A C ; Modic, Živa ; Schuster, Philipp ; Gebauer, Florian ; Haferkamp, Sebastian ; Ball, Claudia R ; Doerner, Johannes ; Engeland, Christine E ; Pernickel, Sophie C S ; Ackermann, Maximilian ; Arelaki, Stella ; Bots, Selas T F ; Zhang, Wenli ; Schmidt, Barbara ; Ehrhardt, Anja ; Hoeben, Rob C ; Achberger, Johannes ; Hartley, Anna ; Haas, Ferdinand V ; Knol, Lisanne I ; Kulkarni, Amit ; Finkbeiner, Maximiliane S C ; Kemp, Vera ; Schäfer, Theresa E ; Jády, Attila ; Poetsch, Anna R ; Kvasnicka, Hans-Michael ; Ungerechts, Guy

BACKGROUNDPancreatic ductal adenocarcinoma (PDAC) is a tumour entity with unmet medical need. To assess the therapeutic potential of oncolytic virotherapy (OVT) against PDAC, different oncolytic viruses (OVs) are currently investigated in clinical trials. However, systematic comparisons of these different OVs in terms of efficacy against PDAC and biomarkers predicting therapeutic response are lacking.METHODSWe screened fourteen patient-derived PDAC cultures which reflect the intra- and intertumoural heterogeneity of PDAC for their sensitivity to five clinically relevant OVs, namely serotype 5 adenovirus Ad5-hTERT, herpes virus T-VEC, measles vaccine strain MV-NIS, reovirus jin-3, and protoparvovirus H-1PV. Live cell analysis, quantification of viral genome/gene expression, cell viability as well as cytotoxicity assays and titration of viral progeny were conducted. Transcriptome profiling was employed to identify potential predictive biomarkers for response to OV treatment.FINDINGSPatient-derived PDAC cultures showed individual response patterns to OV treatment. Twelve of fourteen cultures were responsive to at least one OV, with no single OV proving superior or inferior across all cultures. Known host factors for distinct viruses were retrieved as potential biomarkers. Compared to the classical molecular subtype, the quasi-mesenchymal or basal-like subtype of PDAC was found to be more sensitive to H-1PV, jin-3, and T-VEC. Generally, expression of viral entry receptors did not correlate with sensitivity to OV treatment, with one exception: Expression of Galectin-1 (LGALS1), a factor involved in H-1PV entry, positively correlated with H-1PV induced cell killing. Rather, cellular pathways controlling immunological, metabolic and proliferative signaling appeared to determine outcome. For instance, high baseline expression of interferon-stimulated genes (ISGs) correlated with relative resistance to oncolytic measles virus, whereas low cyclic GMP-AMP synthase (cGAS) expression was associated with exceptional response. Combination treatment of MV-NIS with a cGAS inhibitor improved tumour cell killing in several PDAC cultures and cells overexpressing cGAS were found to be less sensitive to MV oncolysis.INTERPRETATIONConsidering the heterogeneity of PDAC and the complexity of biological therapies such as OVs, no single biomarker can explain the spectrum of response patterns. For selection of a particular OV, PDAC molecular subtype, ISG expression as well as activation of distinct signaling and metabolic pathways should be considered. Combination therapies can overcome resistance in specific constellations. Overall, oncolytic virotherapy is a viable treatment option for PDAC, which warrants further development. This study highlights the need for personalised treatment in OVT. By providing all primary data, this study provides a rich source and guidance for ongoing developments.FUNDINGGerman National Science Foundation (Deutsche Forschungsgemeinschaft, DFG), German Cancer Aid (Deutsche Krebshilfe), German National Academic Scholarship Foundation (Studienstiftung des deutschen Volkes), Survival with Pancreatic Cancer Foundation.

2020-12-01·Leukemia1区 · 医学

Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma

1区 · 医学

Article

作者: Packiriswamy, Nandakumar ; Peng, Kah-Whye ; Zhou, Yumei ; Rooney, Cliona M ; Dispenzieri, Angela ; Diaz, Rosa M ; Russell, Stephen J ; Miller, Amber ; Upreti, Deepak ; Khan, Rehan

AbstractOncolytic virus therapy leads to immunogenic death of virus-infected tumor cells and this has been shown in preclinical models to enhance the cytotoxic T-lymphocyte response against tumor-associated antigens (TAAs), leading to killing of uninfected tumor cells. To investigate whether oncolytic virotherapy can increase immune responses to tumor antigens in human subjects, we studied T-cell responses against a panel of known myeloma TAAs using PBMC samples obtained from ten myeloma patients before and after systemic administration of an oncolytic measles virus encoding sodium iodide symporter (MV-NIS). Despite their prior exposures to multiple immunosuppressive antimyeloma treatment regimens, T-cell responses to some of the TAAs were detectable even before measles virotherapy. Measurable baseline T-cell responses against MAGE-C1 and hTERT were present. Furthermore, MV-NIS treatment significantly (P < 0.05) increased T-cell responses against MAGE-C1 and MAGE-A3. Interestingly, one patient who achieved complete remission after MV-NIS therapy had strong baseline T-cell responses both to measles virus proteins and to eight of the ten tested TAAs. Our data demonstrate that oncolytic virotherapy can function as an antigen agnostic vaccine, increasing cytotoxic T-lymphocyte responses against TAAs in patients with multiple myeloma, providing a basis for continued exploration of this modality in combination with immune checkpoint blockade.

2017-12-01·Leukemia1区 · 医学

Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma

1区 · 医学

Article

作者: Lacy, M Q ; Gertz, M A ; Lowe, V J ; Zhou, Y ; Laumann, K ; Peng, K-W ; Federspiel, M J ; LaPlant, B ; Buadi, F ; Dispenzieri, A ; Tong, C ; Dingli, D ; O'Connor, M ; Hayman, S ; Russell, S J

MV-NIS is an Edmonston lineage oncolytic measles virus expressing the human sodium iodide symporter-a means for monitoring by non-invasive imaging of radioiodine. Patients with relapsed, refractory myeloma who had explored all other treatment options were eligible for this Phase I trial. Cohort 1 was treated with intravenous MV-NIS, and Cohort 2 received cyclophosphamide 2 days prior to MV-NIS. Thirty-two patients were treated. Cohort 1 initially enrolled to four dose levels without reaching maximum tolerated dose (MTD) and subsequently to two higher dose levels when improved virus manufacture technology made it possible. MTD was not reached in Cohort 1, and TCID₅₀ 10¹¹ is the dose being used in a Phase II trial of single agent MV-NIS. Grade 3-4 adverse events in both cohorts at all dose levels were: neutropenia (n=9); leukocyte count decreased (n=5); thrombocytopenia (n=2); and CD4 lymphocytes decreased, anemia and lymphopenia (each n=1). MV-N RNA sequences were amplified from gargle specimens, blood and urine. ¹²³I scans were positive in eight patients. One patient achieved a complete response; transient drops in serum free light chains were seen in other patients. MV-NIS is capable of replicating before being cleared by the immune system. Oncolytic viruses offer a promising new modality for the targeted infection and destruction of disseminated myeloma.

100 项与 Oncolytic measles virus encoding thyroidal sodium iodide symporter(Vyriad, Inc.) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Oncolytic measles virus encoding thyroidal sodium iodide symporter(Vyriad, Inc.)	-	-

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
输卵管癌	临床2期	-	Vyriad, Inc.初创企业	-
卵巢癌	临床2期	-	Vyriad, Inc.初创企业	-
腹膜癌	临床2期	-	Vyriad, Inc.初创企业	-
胶质母细胞瘤	临床1期	美国	Vyriad, Inc.初创企业	-
头颈部肿瘤	临床1期	美国	Vyriad, Inc.初创企业	-
间皮瘤	临床1期	-	Vyriad, Inc.初创企业	-
横纹肌肉瘤	临床1期	-	Vyriad, Inc.初创企业	-
鳞状细胞癌	临床1期	-	Vyriad, Inc.初创企业	-
难治性多发性骨髓瘤	药物发现	美国	University of Arkansas System	2015-03-01
间皮瘤	药物发现	美国	-	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02919449 (CTgov)	临床1期	转移性非小细胞肺癌 \| 复发性非小细胞肺癌	2	atezolizumab+MV-NIS	壓壓齋廠選鑰壓夢網蓋(齋襯觸鑰鏇顧憲遞壓齋) = 築願獵膚膚遞醖窪鬱鏇醖範願獵製構選觸衊艱 (觸觸繭願窪齋憲齋壓積, 觸膚網膚築膚壓願積積 ~ 淵醖範醖餘鹽膚醖膚繭) 更多	-	2023-07-21
NCT03171493 (ASCO_GU2022) 人工标引	临床1期	尿路上皮癌新辅助	8	MV-NIS	(構淵觸選觸鹹窪淵構夢) = Only a single Adverse Event (AE) attributable to MV-NIS treatment (Grade 1 hematuria) 製齋簾鬱築鏇遞築觸衊 (繭網餘衊構繭衊襯築餘 )	积极	2022-02-16
NCT02192775 (CTgov)	临床2期	难治性多发性骨髓瘤	2	MV-NIS	鬱淵繭願願遞糧範繭鑰(鹹齋醖繭願夢鹽鏇鬱廠) = 製糧醖蓋廠鏇網簾繭願膚顧築壓鏇醖醖膚遞膚 (鹽積餘遞願築艱獵繭築, 遞積窪齋範積蓋鑰網遞 ~ 壓鹽範鹽鏇廠遞鹽襯鏇) 更多	-	2020-10-19
WCLC2016	N/A	恶性胸膜间皮瘤二线	12	MV-NIS	(襯餘壓淵廠蓋壓壓遞製) = 艱齋鏇網襯製遞網齋鑰艱餘齋鏇積鹽糧糧餘觸 (選繭範餘鏇壓築鬱憲廠, 221 ~ 484)	-	2016-12-06